To investigate whether DDX5 is downstream of BCR-ABL in CML cells, we examined the effects of the BCR-ABL inhibitor imatinib on the expression of DDX5 in K562 cells. This evidence concerns the gene DDX5 and chronic myelogenous leukemia, BCR-ABL1 positive.